CSL Past Earnings Performance
Past criteria checks 5/6
CSL has been growing earnings at an average annual rate of 3.2%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 11.2% per year. CSL's return on equity is 14%, and it has net margins of 17.9%.
Key information
3.2%
Earnings growth rate
1.6%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | 11.2% |
Return on equity | 14.0% |
Net Margin | 17.9% |
Next Earnings Update | 10 Feb 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How CSL makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 14,800 | 2,642 | 2,381 | 1,428 |
31 Mar 24 | 14,490 | 2,557 | 2,305 | 1,386 |
31 Dec 23 | 14,179 | 2,472 | 2,277 | 1,312 |
30 Sep 23 | 13,745 | 2,333 | 2,317 | 1,274 |
30 Jun 23 | 13,310 | 2,194 | 2,308 | 1,266 |
31 Mar 23 | 12,507 | 2,156 | 2,168 | 1,265 |
31 Dec 22 | 11,705 | 2,118 | 2,028 | 1,263 |
30 Sep 22 | 11,133 | 2,186 | 1,839 | 1,210 |
30 Jun 22 | 10,562 | 2,255 | 1,649 | 1,156 |
31 Mar 22 | 10,587 | 2,290 | 1,711 | 1,108 |
31 Dec 21 | 10,612 | 2,325 | 1,773 | 1,060 |
30 Sep 21 | 10,461 | 2,350 | 1,742 | 1,031 |
30 Jun 21 | 10,310 | 2,375 | 1,712 | 1,001 |
31 Mar 21 | 10,145 | 2,520 | 1,612 | 953 |
31 Dec 20 | 9,980 | 2,665 | 1,511 | 904 |
30 Sep 20 | 9,565 | 2,384 | 1,550 | 913 |
30 Jun 20 | 9,151 | 2,103 | 1,588 | 922 |
31 Mar 20 | 9,048 | 2,054 | 1,557 | 904 |
31 Dec 19 | 8,944 | 2,006 | 1,527 | 886 |
30 Sep 19 | 8,742 | 1,962 | 1,484 | 859 |
30 Jun 19 | 8,539 | 1,919 | 1,442 | 832 |
31 Mar 19 | 8,406 | 1,861 | 1,441 | 791 |
31 Dec 18 | 8,274 | 1,803 | 1,441 | 751 |
30 Sep 18 | 8,094 | 1,766 | 1,371 | 726 |
30 Jun 18 | 7,915 | 1,729 | 1,301 | 702 |
31 Mar 18 | 7,666 | 1,674 | 1,251 | 713 |
31 Dec 17 | 7,417 | 1,618 | 1,200 | 723 |
30 Sep 17 | 7,182 | 1,478 | 1,191 | 695 |
30 Jun 17 | 6,947 | 1,337 | 1,182 | 667 |
31 Mar 17 | 6,802 | 1,333 | 1,118 | 642 |
31 Dec 16 | 6,656 | 1,329 | 1,055 | 617 |
30 Sep 16 | 6,386 | 1,286 | 1,033 | 615 |
30 Jun 16 | 6,115 | 1,242 | 1,011 | 614 |
31 Mar 16 | 5,983 | 1,324 | 954 | 564 |
31 Dec 15 | 5,850 | 1,406 | 897 | 513 |
30 Sep 15 | 5,654 | 1,392 | 841 | 488 |
30 Jun 15 | 5,459 | 1,379 | 786 | 463 |
31 Mar 15 | 5,482 | 1,366 | 768 | 467 |
31 Dec 14 | 5,505 | 1,354 | 750 | 471 |
30 Sep 14 | 5,420 | 1,330 | 773 | 468 |
30 Jun 14 | 5,335 | 1,307 | 797 | 466 |
31 Mar 14 | 5,189 | 1,270 | 803 | 466 |
31 Dec 13 | 5,042 | 1,233 | 810 | 466 |
Quality Earnings: CSJA has high quality earnings.
Growing Profit Margin: CSJA's current net profit margins (17.9%) are higher than last year (16.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CSJA's earnings have grown by 3.2% per year over the past 5 years.
Accelerating Growth: CSJA's earnings growth over the past year (20.4%) exceeds its 5-year average (3.2% per year).
Earnings vs Industry: CSJA earnings growth over the past year (20.4%) exceeded the Biotechs industry -20.8%.
Return on Equity
High ROE: CSJA's Return on Equity (14%) is considered low.